Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 13/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15388269 | 1.00 | CXCR3 (0.61) | CXCR3KDM4ELMNAHTTSMN1; SMN2 | |
| SCHEMBL15392617 | 0.88 | PSEN1 (0.50) | CXCR3LMNASMN1; SMN2PSEN1PSEN2 | |
| SCHEMBL10205301 | 0.88 | PSEN1 (0.50) | CXCR3LMNASMN1; SMN2PSEN1PSEN2 | |
| SCHEMBL15388034 | 0.85 | PSEN1 (0.58) | CXCR3LMNAHTTSMN1; SMN2PSEN1 | |
| SCHEMBL15388164 | 0.85 | SMN1; SMN2 (0.53) | CXCR3LMNASMN1; SMN2PSEN1PSEN2 | |
| SCHEMBL1673932 | 0.85 | SMN1; SMN2 (0.53) | CXCR3LMNASMN1; SMN2PSEN1PSEN2 | |
| SCHEMBL15388048 | 0.83 | PSEN1 (0.56) | CXCR3SMN1; SMN2PSEN1PSEN2APH1B | |
| SCHEMBL10205751 | 0.83 | PSEN1 (0.56) | CXCR3SMN1; SMN2PSEN1PSEN2APH1B | |
| SCHEMBL15388018 | 0.83 | PSEN1 (0.55) | CXCR3SMN1; SMN2PSEN1PSEN2APH1B | |
| SCHEMBL1672561 | 0.83 | PSEN1 (0.55) | CXCR3HTTSMN1; SMN2PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310384-A1 | Sulfonamide-Containing Compounds | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2012047926-A2 | SULFONAMIDE-CONTAINING COMPOUNDS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310384-A1 | Sulfonamide-Containing Compounds | BACE1, BACE2, GSAP | CXCR3 3625/4885KDM4E 1564/4885LMNA 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.